# Trial of Imatinib for Hospitalized Adults With COVID-19

> **NCT04394416** · PHASE3 · TERMINATED · sponsor: **University of Maryland, Baltimore** · enrollment: 21 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04394416
- **Lead sponsor:** University of Maryland, Baltimore
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-02
- **Primary completion:** 2024-06-30
- **Final completion:** 2025-07-17
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** The Principal Investigator left the institution. The study was halted prematurely.
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04394416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04394416, "Trial of Imatinib for Hospitalized Adults With COVID-19". Retrieved via AI Analytics 2026-07-24 from https://api.ai-analytics.org/clinical/NCT04394416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*